Branched Peptides & Mini Proteins

From Tirzepatide with a peptidic half-life extension component on a lysine side chain, to novel antivirals with polydentate binding modes, to computationally designed mini protein binders that rival antibody specificity—branched peptides and mini proteins offer conceptually simple, low-risk approaches to improving existing leads and introducing novel functionalities. At Amide, we’re uniquely suited to rapidly manufacture these complex constructs, so you can focus on investigating their pharmacological possibilities.

Branched Peptides: Multiplying Functionality

Branched peptides feature multiple peptide chains extending from a central core, creating tree-like architectures that introduce multivalency for enhanced target engagement, spatial control over pharmacophore positioning, improved metabolic stability, and tunable pharmacokinetics.

Clinical Validation

Tirzepatide (Mounjaro®, Zepbound®) – Dual GIP/GLP-1 agonist with C20 fatty diacid via lysine branch, achieving once-weekly dosing

Degarelix (Firmagon®) – GnRH antagonist with strategic D-amino acid branching

Multiple Antigen Peptides (MAPs) – Branched vaccine constructs with robust immunogenicity

These billion-dollar therapeutics validate branched architectures as a proven modality.

Branching Strategies

Lysine branching – Most common in approved drugs, enabling attachment of lipids, PEG, sequences, or small molecules

Alternative amino acids – Ornithine and diaminopropionic acid for varied geometries

Non-natural scaffolds – Dendrimers for higher-order branching

Disulfide connectivity – Cysteine placement creates branched topologies

Chemoselective conjugation – Click chemistry, native chemical ligation, or enzymatic methods

Applications

Half-life extension • Bispecific constructs • Peptide-drug conjugates • Enhanced cell penetration • Vaccine development • Proteolytic stability

Mini Proteins: Precision in a Compact Package

Mini proteins (40-60 amino acids) are the smallest polypeptides capable of autonomous folding into stable 3D structures. They offer antibody-like specificity with chemical synthesis accessibility, oral bioavailability potential, low immunogenicity, and rapid tissue penetration.

Computational Design Revolution

Rosetta and AlphaFold enable design of novel folds with atomic precision against challenging targets. Chemically synthesized libraries allow rapid affinity maturation without recombinant constraints, creating therapeutics that inhibit SARS-CoV-2, neutralize toxins, or modulate “undruggable” targets.

Scaffolds & Applications

Scaffolds: Cysteine-rich frameworks • Zinc fingers • Immunoglobulin mimetics • De novo folds • Mirror image proteins

Applications: Receptor modulation • PPI inhibition • Enzyme inhibition • Molecular imaging • Cell penetration • Toxin neutralization

Why Amide Makes It Easy

Traditional synthesis struggles with these complex structures: steric hindrance, aggregation, multiple disulfides, and critical structure-function relationships. Amide’s AFPS platform solves these challenges:

Rapid optimization enables quick iteration on conditions and protecting groups

Orthogonal protection provides precise control over disulfides and branch points

Seamless scaling from milligrams to grams without reoptimization

The result? Constructs that would take months or prove impossible with conventional methods are delivered in weeks with the purity and scale your program demands.

Get Started

With Amide, the synthesis challenge is solved. You no longer have to wonder “how am I going to get my peptides?”

Ready to discuss your project? Contact our team to learn how AFPS can accelerate your program from design to development.

FREQUENTLY ASKED QUESTIONS

What's the longest sequence you can make?

Mini proteins up to 150 amino acids; branched constructs exceeding 100 total residues.

How do you control multiple disulfide bonds?

Orthogonal protecting groups (Trt, Acm, tBu) for directed formation, or optimized oxidative folding.

Can you make D-amino acid versions?

Yes. Full D-proteins or L/D chimeras offering complete protease resistance.

What purity and timeline?

Routinely >95% purity (>98% achievable). Discovery scale (5-50 mg) in 2-4 weeks.

What scale?

Milligrams for screening to grams for clinical development, scaling without reoptimization.

Do you help with design?

We provide synthesis-focused consultation to improve feasibility, folding, and developability.

What modifications can you add?

Fluorophores, biotin, fatty acids, click handles, and site-specific attachments. We coordinate for specialized conjugations.

What if folding fails?

Folding optimization is included. We explore conditions systematically and suggest sequence modifications if needed.